Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial-Reference-Cited by-同舟云学术

Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial

Published:2003-04 Issue:2 Volume:24 Page:224-243
ISSN:0197-2456
Container-title:Controlled Clinical Trials
language:en
Short-container-title:Controlled Clinical Trials

Author:

Bautista Oliver M,Kusek John W,Nyberg Leroy M,McConnell John D,Bain Raymond P,Miller Gary,Crawford E.David,Kaplan Steven A,Sihelnik Stephen A,Brawer Michael K,Lepor Hebert

Publisher

Elsevier BV

Subject

Pharmacology

Reference57 articles.

1. Benign prostatic hyperplasia;McConnell,1994

2. Transurethral prostatectomy;Holtgrewe;J Urology,1989

3. Transurethral prostatectomy;Mebust;J Urology,1989

4. Medical therapy in benign prostatic hyperplasia: full-scale trial. NIH Guide Volume 23, Number 22, June 10, 1994.

5. Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia;Lepor;Urology,1988

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Change in prostate tissue gene expression following finasteride or doxazosin administration in the medical therapy for prostatic symptoms (MTOPS) study;Scientific Reports;2024-08-19

2. The GG genotype of rs743572 in CYP17A1 gene regulating the decrease of T/E ratio can be an independent risk factor for MetS-BPH: a retrospective cohort study;World Journal of Urology;2024-07-24

3. Enhanced prostatic Esr1⁺ luminal epithelial cells in the absence of SRD5A2;The Journal of Pathology;2024-04-12

4. α1-adrenoceptor antagonists and 5α-reductase inhibitors for urinary tract symptoms in benign prostatic hyperplasia;Journal of Paramedic Practice;2024-02-02

5. Transcriptomic analysis of benign prostatic hyperplasia identifies critical pathways in prostatic overgrowth and 5‐alpha reductase inhibitor resistance;The Prostate;2024-01-03